O'Day said today that they would have enough Rem to meet world demand at end of month, but also acknowledged that the study shows greatest impact when taken early. If they combine with Lenzilumab they would have a wider reach and have an inhouse backstop that will work when Rem doesn't get the job done. Reg and Lly are swooping in and stealing Gileads headlines and stock MoMo, and I don't know how much longer he is going to standby. Thier shareholders need to see him swing back, and this combination could keep them in the go to position here. We all know the real value of Lenz here and how important it is as the Cleanup Hitter in Covid, when the other options fail it will be up to Lenzilumab to cleanup.
News 
Market Data 
Discover 
